IDH1 and acute myeloid leukemia: The IDH2 inhibitor Enasidenib (AG-221) and Ivosidenib are approved for relapsed/refractory AML in the presence of relevant mutations and ivosidenib was recently approved, in combination with hypomethylating agents, as first-line therapy for IDH1 mutant AML [Figure 1].